{"publication_id":"feeb5f66-90ca-44c5-8038-6eb67934c744","content_hash":"sha256:244fb007a00625f741c339f2eec4471b0c1d608827aa1b843cdd82423cff9a1d","nodes":[{"id":"feeb5f66-90ca-44c5-8038-6eb67934c744","type":"publication","title":"Age and Disease Severity as Determinants of Stem Cell Fitness in Autologous HSCT for Systemic Sclerosis: Implications for Exhaustion-Driven Outcomes"},{"id":"claim_1","type":"claim","text":"The cited A/B receipts support a specific working claim: Thrombotic microangiopathy may affect multiple systems and occurs in ~30% of patients undergoing hematopoietic stem cell transplantation; AKI occurs commonly after stem cell transplant, affecting 10%-73% of patients. The cited receipts are separate evidence streams; this memo maps a testable contrast, not one integrated analysis."},{"id":"claim_2","type":"claim","text":"Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication."},{"id":"claim_3","type":"claim","text":"The critical, underappreciated role of patient age and baseline disease severity in modulating stem cell therapy efficacy, suggesting that stem cell exhaustion may drive differential outcomes in autoimmune and metabolic disorders, despite overall positive trends."},{"id":"claim_4","type":"claim","text":"Known / obvious (do not republish): Overall survival rates exceed 90% in pediatric HCT recipients; Stem cell therapy reduces HbA1c and C-peptide in diabetic patients; Non-relapse mortality in HSCT has decreased significantly over decades"},{"id":"claim_5","type":"claim","text":"Bounded research question:** Does the cited receipt bundle still support this bounded claim when population, endpoint, comparator, and time window are aligned?"},{"id":"claim_6","type":"claim","text":"_Within the currently bound receipt bundle, no A_core/B_context opposing fact was selected. Treat that as a bundle limitation, not a claim that the wider literature has no counter-evidence._"},{"id":"source_1","type":"source","study":"Hematopoietic cell transplantation-associated thrombotic microangiopathy: a review of pathophysiology, diagnosis, and treatment","year":2016,"doi":"10.2147/jbm.s102235","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_2","type":"source","study":"Acute Kidney Injury and CKD Associated with Hematopoietic Stem Cell Transplantation","year":2019,"doi":"10.2215/cjn.08580719","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_3","type":"source","study":"Cardiovascular Management of Patients Undergoing Hematopoietic Stem Cell Transplantation: From Pretransplantation to Survivorship: A Scientific Statement From the American Heart Association","year":2024,"doi":"10.1161/cir.0000000000001220","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_4","type":"source","study":"Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party","year":2020,"doi":"10.3324/haematol.2019.230128","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_5","type":"source","study":"A Review of Chronic Granulomatous Disease","year":2017,"doi":"10.1007/s12325-017-0636-2","url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"}],"edges":[{"from":"feeb5f66-90ca-44c5-8038-6eb67934c744","to":"claim_1","type":"contains_claim"},{"from":"feeb5f66-90ca-44c5-8038-6eb67934c744","to":"claim_2","type":"contains_claim"},{"from":"feeb5f66-90ca-44c5-8038-6eb67934c744","to":"claim_3","type":"contains_claim"},{"from":"feeb5f66-90ca-44c5-8038-6eb67934c744","to":"claim_4","type":"contains_claim"},{"from":"feeb5f66-90ca-44c5-8038-6eb67934c744","to":"claim_5","type":"contains_claim"},{"from":"feeb5f66-90ca-44c5-8038-6eb67934c744","to":"claim_6","type":"contains_claim"}],"screening":{"identified":5,"screened":5,"excluded":0,"included":5,"included_or_retained":5,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"5 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]}}